A first clinical trial aimed at prevention of GvHD and establishment of immunological tolerance after haplo-HSCT with purified CD34+ cells in adult with high risk leukemias was carried out using donor Tr1 cells specific for host alloantigens (73). Here, CD34 is linked to graft versus host disease.